Advertisement

Volume 1, Issue 12

 

Cover Image

Cover Figure: Transcription factor TLX3 and miR-125b function link.
See the article by Li et al.

Join the discussion @ Blood Advances Community Conversations

WASHINGTON, May 9,  2017 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

The retrovirus human T-cell lymphotropic virus type 1 is the cause of adult T-cell leukemia/lymphoma, which carries a dismal prognosis. Recently, the combination of zidovudine and interferon alfa has been shown to be an effective treatment for this challenging disease. In a Stimulus Report, Macchi et al examine the reverse transcriptase (RT) activity in cultures of peripheral blood mononuclear cells from patients before and after therapy, showing that combination treatment completely inhibits RT activity and also reduces other virologic assays.

There has been much interest in the use of elotuzumab, a humanized monoclonal antibody that binds to hSLAMF7, to treat patients with multiple myeloma. This agent is known to impact natural killer cells and enhance their biological function. In the study by Bezman et al, this agent was combined with anti–PD-1, resulting in interesting biological effects.

The management of patients with a history of thromboembolic events who undergo autologous hematopoietic cell transplantation is a significant challenge because of the prolonged thrombocytopenia these patients experience. There are no established guidelines for how to treat these often complex patients. Li et al evaluated 204 such patients, some of whom had anticoagulation held during thrombocytopenic periods and others who did not. This paper provides important guidance on this challenging clinical situation.

Featured Visual Abstract

X-ray crystal structure of plasmin with tranexamic acid–derived active site inhibitors

Ruby H. P. Law, Guojie Wu, Eleanor W. W. Leung, Koushi Hidaka, Adam J. Quek, Tom T. Caradoc-Davies, Devadharshini Jeevarajah, Paul J. Conroy, Nigel M. Kirby, Raymond S. Norton, Yuko Tsuda, James C. Whisstock

 

 

 

 

Blood Advances is the official open-access journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.